Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U.

Eur J Cancer. 2011 Jul;47(11):1633-46. doi: 10.1016/j.ejca.2011.03.006. Epub 2011 Apr 7.

PMID:
21482103
2.

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U.

GMS Health Technol Assess. 2010 Apr 27;6:Doc05. doi: 10.3205/hta000083.

3.
4.

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.

Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C.

Gynecol Oncol. 2009 Feb;112(2):377-83. doi: 10.1016/j.ygyno.2008.08.030. Epub 2008 Dec 11.

PMID:
19081611
5.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
6.

Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries.

Maxwell GL, Carlson JW, Ochoa M, Krivak T, Rose GS, Myers ER.

Obstet Gynecol. 2002 Oct;100(4):740-8.

PMID:
12383543
7.

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.

Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N.

Health Technol Assess. 2004 May;8(20):iii, 1-78. Review.

8.

[Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment].

Zhao FH, Chen JF, Gao XH, Gao LM, Liu QG, Liu ZH, Xu H, Ma JF, Ma L, Xu XL, Hu SY, Ning Y, Shi JF, Qiao YL.

Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):632-6. doi: 10.3760/cma.j.issn.0253-3766.2012.08.017. Chinese.

PMID:
23159002
9.

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.

Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM.

Am J Med. 2001 Aug;111(2):140-9.

PMID:
11498068
10.

Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.

Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Chernofsky M, Myers ER.

Obstet Gynecol. 2006 May;107(5):997-1005.

PMID:
16648402
11.

The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.

Wong G, Howard K, Webster A, Chapman JR, Craig JC.

Transplantation. 2009 Apr 15;87(7):1078-91. doi: 10.1097/TP.0b013e31819d32eb.

PMID:
19352131
12.

Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.

Chen MK, Hung HF, Duffy S, Yen AM, Chen HH.

J Eval Clin Pract. 2011 Dec;17(6):1050-8. doi: 10.1111/j.1365-2753.2010.01453.x. Epub 2011 Jun 16.

PMID:
21679279
13.

Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.

Obradovic M, Mrhar A, Kos M.

Eur J Public Health. 2010 Aug;20(4):415-21. doi: 10.1093/eurpub/ckp208. Epub 2010 Jul 12.

PMID:
20624834
14.

Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.

Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, King J, Yi B, Ringers P, Blumenthal PD.

J Natl Cancer Inst. 2002 Oct 2;94(19):1469-83.

PMID:
12359856
15.

Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.

Östensson E, Hellström AC, Hellman K, Gustavsson I, Gyllensten U, Wilander E, Zethraeus N, Andersson S.

Acta Obstet Gynecol Scand. 2013 Jul;92(7):830-40. doi: 10.1111/aogs.12143. Epub 2013 Apr 22. Erratum in: Acta Obstet Gynecol Scand. 2013 Aug;92(8):994.

PMID:
23530870
16.

Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden.

Ostensson E, Fröberg M, Hjerpe A, Zethraeus N, Andersson S.

Acta Obstet Gynecol Scand. 2010 Oct;89(10):1316-25. doi: 10.3109/00016349.2010.512066. Erratum in: Acta Obstet Gynecol Scand. 2010 Nov;89(11):1497.

PMID:
20846064
17.

Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.

Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P.

Can J Public Health. 2010 May-Jun;101(3):220-5.

PMID:
20737813
18.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.

Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.

BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x. Epub 2011 Apr 12.

19.

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group.

J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.

PMID:
16418511
20.

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.

J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

PMID:
15100338

Supplemental Content

Support Center